延龄草化学成分及抗乳腺癌活性筛选研究
doi: 10.11931/guihaia.gxzw202504022
代红梅 1 , 王文哲 1 , 张慧子 1 , 赵艳君 2 , 田胜乐 1 , 白现广 1
1. 平顶山学院 医学院,河南 平顶山 467006
2. 联勤保障部队第九八九医院,河南 平顶山 467009
基金项目: 河南省科技攻关项目(252102311028)。
Chemical constituents and their anti-breast cancer activities of Trillium tschonoskii
DAI Hongmei 1 , WANG Wenzhe 1 , ZHANG Huizi 1 , ZHAO Yanjun 2 , TIAN Shengle 1 , BAI Xianguang 1
1. College of Medicine, Pingdingshan University, Pingdingshan 467006, Henan, China
2. The 989th Hospital of the Joint Logistics Support Force, Pingdingshan 467009, Henan, China
摘要
为探讨延龄草化学成分及其对乳腺癌细胞的影响,该研究采用硅胶和Sephadex LH-20对延龄草提取物进行分离纯化,根据理化性质和波谱数据鉴定化合物的结构,并采用MTT法评价化合物对乳腺癌细胞株MDA-MB-231的抑制活性。结果表明:(1)从延龄草中鉴定出24个化合物,分别为lysicamine(1)、hydroxyframoside(2)、goniothalamusin(3)、pyrocatechol(4)、6-羟基-7,8-二甲氧基香豆素(5)、norisoboldine(6)、4,6-二羟基-2-甲氧基苯乙酮(7)、hinokiresinol(8)、sedanolide(9)、rostratamine(10)、cinnamicacid(11)、magnolioside(12)、platypterophathalide(13)、transtorine(14)、capillasterolide(15)、globularin(16)、芒柄花素(17)、对羟基肉桂酸乙酯(18)、cirsilineol(19)、地芰普内酯(20)、acetoisovanillone(21)、rubrosterone(22)、didehydroconicol(23)、去氢吐叶醇(24);所有化合物均首次从延龄草中分离鉴定。(2)化合物14891314161923对MDA-MB-231细胞具有不同程度的抑制作用,其中化合物9对MDA-MB-231细胞的抑制作用与环磷酰胺相当(P>0.05)。该研究结果揭示了延龄草的化学成分,其中化合物9具有潜在的抗乳腺癌活性。
Abstract
In order to investigate the chemical constituents of Trillium tschonoskii and their effects on breast cancer cells. The extract of T. tschonoskii was isolated and purified by silica gel and Sephadex LH-20. The structures of the compounds were identified based on physicochemical properties and spectral data. The inhibitory activities of the compounds against the breast cancer cell line MDA-MB-231 were evaluated by the MTT method. The results were as follows: (1) Twenty-four compounds were identified from T. tschonoskii, namely lysicamine (1), hydroxyframoside (2), goniothalamusin (3), pyrocatechol (4), 6-hydroxy-7, 8-dimethoxycoumarin (5), norisoboldine (6), 4,6-dihydroxy-2-methoxyacetophenone (7), hinokiresinol (8), sedanolide (9), rostratamine (10), cinnamicacid (11), magnolioside (12), platypterophathalide (13), transtorine (14), capillasterolide (15), globularin (16), ononin (17), ethyl p-hydroxycinnamate (18), cirsilineol (19), loliolide (20), acetoisovanillone (21), rubrosterone (22), didehydroconicol (23), dehydrovomifoliol (24); all compounds were isolated and identified from T. tschonoskii for the first time. (2) Compounds 1, 4, 8, 9, 13, 14, 16, 19, 23 had inhibitory effects of varying degrees on MDA-MB-231 cells. Among them, the inhibitory effect of Compound 9 on MDA-MB-231 cells was comparable to that of cyclophosphamide (P>0.05). The results of this study reveal the chemical constituents of T. tschonoskii, among which Compound 9 has potential anti-breast cancer activity.
药材延龄草为百合科延龄草属植物延龄草(Trillium tschonoskii)、西藏延龄草(T. govanianum)和吉林延龄草(T. kamtschaticum)的根及根茎,又称三角七、天株根、地珠(中国科学院武汉植物所,2003)。延龄草主产于东亚和北美洲,在我国主要分布于河南、河北、吉林、辽宁、安徽、陕西等地。《本草纲目拾遗》:“延龄草根捣敷疮毒,能消肿散结”。延龄草性微温味甘苦,功效为解毒消痈、镇静安神和祛风止痛,临床用于蛇虫咬伤、风湿痹痛、疮痈肿毒、心悸、神经衰弱和月经不调等(Khan et al., 2016)。延龄草化学成分主要为甾体皂苷、酚酸、倍半萜、香豆素、苯丙素和多糖(Zhong et al., 2013)。药理作用表明延龄草具有抗肿瘤、抗凝、抗炎、镇痛、镇静催眠、保护心肌和调节免疫等活性(李小沛等,2017)。曾小聪等(2019)研究表明,延龄草乙醇提取物可抑制裸鼠乳腺癌细胞 MDA-MB-231细胞的增值,并促进其凋亡。
延龄草是临床治疗乳腺癌的常用药物,为探讨其治疗抑制乳腺癌细胞的物质基础,笔者对延龄草进行了分离纯化,共鉴定出24个化合物,所有化合物均为首次从延龄草中分离鉴定。对所得化合物抑制乳腺癌细胞株MDA-MB-231的活性测试结果显示,多种单体化合物对MDA-MB-231的增值具有抑制活性,其中化合物sedanolide(化合物9)对MDA-MB-231细胞增殖的抑制率较高,可能具有潜在抗乳腺癌活性。
1 材料与方法
1.1 仪器和试剂
ICP-MS型质谱仪(美国Agilent公司);Spinsolve型核磁共振仪(新西兰Magritek公司);PURA22型恒温电热水浴锅(德国Julabo公司);N-1300型旋转蒸发仪(日本Eyela公司);PBB8型分析天平(美国Prima公司);HydroH24型电子天平(德国Lauda公司);T200型超声清洗仪(瑞士Telsonic公司);B2000型吸收光酶标仪(美国Branson公司);Sephadex LH-20凝胶(美国 GE Healthcare公司);柱色谱硅胶(青岛海洋化工厂);MTT(噻唑蓝,南京绿合生化技术有限公司);DMSO(二甲基亚砜,湖南沃凯生物科技有限公司);乳腺癌细胞株MDA-MB-231(美成都零六生物科技有限公司)。提取分离试剂为分析纯。
1.2 药材
延龄草采自河南省宝丰县,由平顶山学院白现广副教授鉴定为延龄草的根及根茎。
1.3 研究方法
1.3.1 提取与分离
取延龄草13. 5 kg,粉碎为粗粉,用80%甲醇50 L浸泡6 h,超声提取。减压浓缩得浸膏729. 3 g。将浸膏分散于水中,依次用石油醚、二氯甲烷、正丁醇萃取,减压浓缩后得到不同溶剂的萃取浸膏。
取石油醚浸膏(31. 4 g),经硅胶柱色谱,以正己烷-丙酮(75∶25→25∶75,V/V,下同)梯度洗脱,得Fr.AI-VI。取Fr.AⅡ,经硅胶柱色谱,以正己烷-乙酸乙酯(90∶10→10∶90)梯度洗脱,得Fr.AⅡ-1-Fr.AⅡ-6。取Fr.AⅡ-1,经硅胶柱色谱,以正己烷-乙酸乙酯(35∶65)洗脱,得化合物1(19 mg);取Fr.AⅡ-3,经Sephadex LH-20分离,用甲醇洗脱,得化合物9(22 mg);取Fr.AⅡ-6,经硅胶柱色谱,以正己烷-乙酸乙酯(35∶65)洗脱,得化合物2(24 mg)和化合物3(21 mg)。取Fr.AⅢ,经硅胶柱色谱,以正己烷-乙酸乙酯(90∶10→10∶90)梯度洗脱,得Fr.AⅢ-1-Fr.AⅢ-7。取Fr.AⅢ-2,经硅胶柱色谱,以正己烷-乙酸乙酯(35∶65) 洗脱,得化合物12(24 mg);取Fr.AⅢ-3,经重结晶,得化合物4(22 mg)和化合物24(27 mg)。
取二氯甲烷浸膏(31. 6 g),经硅胶柱色谱,以正己烷-丙酮(70∶30→0∶100) 梯度洗脱,得Fr.BI-V。取Fr.BI,经硅胶柱色谱,以正己烷-乙酸乙酯(70∶30→0∶100) 梯度洗脱,得Fr.BI-1-Fr.BI-6。取Fr.BI-2,经硅胶柱色谱,以正己烷-乙酸乙酯(20∶80) 洗脱,得化合物7(22 mg);取Fr.BI-3,经重结晶,得化合物8(20 mg);取Fr.BI-5,经Sephadex LH-20分离,用甲醇洗脱,得化合物10(20 mg)和化合物11(23 mg)。取Fr.BⅢ,经硅胶柱色谱,以正己烷-乙酸乙酯(70∶30→0∶100)梯度洗脱,得Fr.BⅢ-1-Fr.BⅢ-6。取Fr.BⅢ-2,经重结晶,得化合物16(24 mg)和化合物17(21 mg);取Fr.BⅢ-4,经Sephadex LH-20分离,用甲醇洗脱,得化合物21(22 mg)和化合物23(28 mg)。
取正丁醇浸膏(24. 6 g),经硅胶柱色谱,以正己烷-甲醇(85∶15→15∶85)梯度洗脱,得Fr.CI-IV。取Fr.CI,经硅胶柱色谱,以正己烷-甲醇(85∶15→15∶85)梯度洗脱,得Fr.CI-1-Fr.CI-5。取Fr.CI-1,经硅胶柱色谱,以正己烷-甲醇(35∶65)洗脱,得化合物5(25 mg)和化合物6(22 mg);取Fr.CI-2,经硅胶柱色谱,以正己烷-甲醇(35∶65)洗脱,得化合物13(21 mg)、14(22 mg)、15(24 mg);取Fr.CI-4,经重结晶,得化合物18(20 mg)。取Fr.CⅢ,经硅胶柱色谱,以正己烷-甲醇(35∶65)洗脱,得Fr.CⅢ-1-Fr.CⅢ-6。取Fr.CⅢ-2,经硅胶柱色谱,以正己烷-甲醇(35∶65)洗脱,得化合物19(23 mg)和化合物20(21 mg);取Fr.CⅢ-3,经重结晶,得化合物22(26 mg)。
1.3.2 化合物对乳腺癌细胞抑制活性实验
采用MTT法(Niu et al., 2002)评价所得化合物对乳腺癌MDA-MB-231细胞的抑制活性。第一步:取对数生长期的MDA-MB-231细胞,制备成浓度为每毫升3×104个单细胞的悬液;接种于96孔板(每孔100 μL),于36.8 ℃恒温培养箱中预培养24 h;随后分别加待测化合物1-24(设置1.0、10.0、50.0、100.0 μg·mL-1 4个浓度梯度),等量DMSO培养液(作为空白对照组),继续培养24 h;每孔加入10 μL MTT溶液孵育12 h后,采用酶标仪检测吸光度。第二步:取对MDA-MB-231细胞具有抑制活性的化合物,以环磷酰胺作为阳性对照组。将浓度为每毫升3×104个单细胞的悬液接种于96孔板(每孔100 μL)培养24 h;随后分别加对MDA-MB-231细胞具有抑制活性的化合物(设置1.0、5.0、10.0、25.0、50.0、100.0 μg·mL-1 6个浓度梯度)及环磷酰胺,培养24 h。每孔加入10 μL MTT溶液孵育12 h后,加入DMSO溶液溶解后吸弃上清。采用酶标仪检测吸光度,计算IC50值。
2 结果与分析
2.1 结构鉴定
化合物结构鉴定如图 1所示。
1 化合物 1-24 的化学结构
Fig. 1 Chemical structures of compounds 1-24
​化合物1​   黄色粉末,ESI-MS m/z​: 316.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 8.91 ( 1H, d, J​ =11.4 Hz, H-11 ), 8.62 ( 1H, d, J​ = 11.4 Hz, H-5 ), 8.27 ( 1H, d, J​ = 11.4 Hz, H-8 ), 8.13 ( 1H, dd, J​ = 11.4, 4.2 Hz, H-4 ), 7.83 ( 1H, d, J​ = 11.4 Hz, H-10 ), 7.64 ( 1H, dd, J​ = 11.4, 4.2 Hz, H-9 ), 7.51 ( 1H, s, H-3), 3.97 ( 6H, s, 1-OCH3​), 3.82 ( 6H, s, 2-OCH3​ )。13​C-NMR ( 150 MHz, DMSO-d6​ ) δ​: 137.5 ( C-1), 141.6 ( C-2), 95.6 ( C-3), 119.2 ( C-4), 131.9 ( C-5), 142.9 ( C-6), 173.6 ( C-7), 113.6 ( C-8), 108.6 ( C-9), 121.6 ( C-10), 113.8 ( C-11), 57.6 ( 1-OCH3​ )。以上数据与Sulaiman等(2024)报道的数值基本一致,故鉴定化合物1​为lysicamine。
​化合物2  ​ 白色粉末,ESI-MS m/z​: 670.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.63 (1H, s, H-3), 6.93 (1H, d, J​=11.4 Hz, H-8″), 6.91 (1H, d, J​=11.4 Hz, H-4″), 6.71 (1H, overlap, H-5″), 6.68 (1H, overlap, H-7″), 6.71 (1H, overlap, H-4'''), 6.59 (1H, overlap, H-7'''), 6.51 (1H, dd, J​=11.4, 4.2 Hz, H-8'''), 5.94 (1H, m, H-8), 5.72 (1H, brs, H-1), 4.81 (1H, d, J​=11.4 Hz, H-1′), 4.36 (2H, m, H-1″), 4.17 (1H, m, H-1'''β), 4.03 (1H, m, H-5), 4.01 (1H, m, H-6′α), 3.97 (1H, dt, J​=11.4, 4.2 Hz, H-1'''α), 3.52 (1H, m, H-6′β), 3.47 (1H, m, H-2′), 3.32 (1H, m, H-3′), 3.27 (1H, m, H-4′), 3.24 (1H, m, H-5′), 2.74 (2H, t, J​=11.4 Hz, H-2″), 2.71 (2H, t, J​=11.4 Hz, H-2'''), 2.53 (1H, dd, J​=11.4, 4.2 Hz, H-6β), 2.21 (1H, dd, J​=11.4, 4.2 Hz, H-6α), 1.68 (3H, d, J​=11.4 Hz, H-10)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 95.2 (C-1), 143.2 (C-2), 146.5 (C-3), 97.8 (C-4), 36.7 (C-5), 43.8 (C-6), 158.3 (C-7), 121.7 (C-8), 124.3 (C-9), 19.5 (C-10), 153.8 (C-11), 94.8 (C-1′), 72.6 (C-2′), 77.1 (C-3′), 70.3 (C-4′), 77.5 (C-5′), 61.3 (C-6′), 65.2 (C-1″), 36.1 (C-2″), 128.4 (C-3″), 127.4 (C-4″), 115.8 (C-5″), 156.4 (C-6″), 115.4 (C-7″), 130.4 (C-8″), 70.2 (C-1'''), 33.9 (C-2'''), 127.1 (C-3'''), 116.8 (C-4'''), 145.1 (C-5'''), 145.3 (C-6'''), 113.4 (C-7'''), 120.8 (C-8''')。以上数据与冯小涛等(2024)报道的基本一致,故鉴定化合物2​为hydroxyframoside。
​化合物3​   黄色油状物,ESI-MS m/z​: 413.2 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 5.79 (1H, ddt, J​ = 11.4, 4.2, 1.8 Hz, H-21), 5.13 (1H, dd, J​ = 11.4, 4.2 Hz, H-22), 5.07 (1H, d, J​ = 11.4 Hz, H-22), 4.62 (1H, m, H-24), 3.91 (1H, dd, J​ = 11.4, 4.2 Hz, H-25), 3.73 (1H, dd, J​ = 11.4, 4.2 Hz, H-25), 2.71 (1H, m, H-2), 2.34 (1H, m, H-23), 2.09 (2H, t, J​ = 11.4 Hz, H-12), 2.02 (2H, t, J​ = 11.4 Hz, H-15), 1.94 (2H, m, H-20), 1.87 (1H, m, H-23), 1.79 (1H, m, H-3), 1.32~1.51 (14H, m, H-5-11), 1.15~1.27 (8H, m, H-16-19), 1.09 (1H, m, H-3), 1.06 (2H, m, H-4)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 171.3 (C-1), 41.5 (C-2), 32.9 (C-3), 28.9~29.7 (C-4-11), 19.1 (C-12), 76.8 (C-13), 79.1 (C-14), 20.4 (C-15), 27.3~28.5 (C-16-19), 34.1 (C-20), 140.2 (C-21), 109.2 (C-22), 30.2 (C-23), 79.1 (C-24), 65.3 (C-25)。以上数据与Seidel(1999)报道的数值基本一致,故鉴定化合物3​为goniothalamusin。
​化合物4​   白色结晶,ESI-MS m/z​: 133.0 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.62 (2H, d, J​ = 11.4 Hz, H-3, 4), 6.83 (2H, d, J​ = 11.4 Hz, H-2, 5)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 143.5 (C-1), 113.8 (C-2), 127.5 (C-3), 127.5 (C-4), 113.8 (C-5), 43.5 (C-6)。以上数据与傅小雅等(2024)报道的数值基本一致,故鉴定化合物4​为pyrocatechol。
​化合物5​   白色粉末,ESI-MS m/z​: 245.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.62 (1H, d, J​ = 11.4 Hz, H-4), 6.81 (1H, s, H-5), 6.35 (1H, d, J​ = 11.4 Hz, H-3), 4.09 (3H, s, 7-OCH3​), 4.03 (3H, s, 8-OCH3​)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 134.2 (C-1), 167.8 (C-2), 113.8 (C-3), 151.7 (C-4), 110.6 (C-5), 135.8 (C-6), 132.8 (C-7), 135.8 (C-8), 181.6 (C-9), 108.5 (C-10), 62.4 (8-OCH3​), 60.2 (7-OCH3​)。以上数据与傅小雅等(2024)报道的数值基本一致,故鉴定化合物5​为6-羟基-7, 8-二甲氧基香豆素。
​化合物6​   白色粉末,ESI-MS m/z​: 336.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.56 (1H, s, H-11), 6.53 (1H, s, H-3), 6.41 (1H, s, H-8), 4.16 (1H, dd, J​=11.4, 4.2 Hz, H-7), 3.52 (3H, s, 2-OCH3​), 3.49 (3H, s, 10-OCH3​), 3.25~3.41 (2H, m, H-4), 2.92~3.14 (4H, m, H-5, 6)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 146.2 (C-1), 138.2 (C-2), 103.5 (C-3), 27.4 (C-4), 41.9 (C-5), 56.9 (C-6), 35.1 (C-7), 113.8 (C-8), 142.6 (C-9), 137.9 (C-10), 109.5 (C-11), 59.7 (2-OCH3​), 57.1 (10-OCH3​)。以上数据与傅小雅等(2024)报道的数值基本一致,故鉴定化合物6​为norisoboldine。
​化合物7​   白色针晶,ESI-MS m/z​: 204.9 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 6.03 (1H, d, J​ = 2.1 Hz, H-3), 5.74 (1H, d, J​ = 11.4 Hz, H-5), 2.43 (3H, s, 2-COCH3​)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 105.3 (C-1), 167.4 (C-2), 97.1 (C-3), 153.9 (C-4), 93.6 (C-5), 148.6 (C-6), 34.3 (2-COCH3​)。以上数据与许浩楠等(2024)报道的数值基本一致,故鉴定化合物7​为4, 6-二羟基-2-甲氧基苯乙酮。
​化合物8​   黄色粉末,ESI-MS m/z​: 275.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.09 (2H, d, J​ = 11.4 Hz, H-2′, 6′), 6.93 (2H, d, J​ = 11.4 Hz, H-2, 6), 6.64 (4H, dd, J​ = 11.4, 4.2 Hz, H-3, 5, 3′, 5′), 6.58 (1H, m, H-8′), 6.32 (1H, d, J​ = 11.4 Hz, H-7′), 5.93 (1H, ddd, J​ = 11.4, 4.2, 1.8 Hz, H-8), 5.08 (2H, dd, J​ = 11.4, 4.2 Hz, H-9)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 127.3 (C-1), 130.5 (C-2), 108.6 (C-3), 143.5 (C-4), 108.6 (C-5), 130.5 (C-6), 57.1 (C-7), 135.2 (C-8), 109.2 (C-9), 116.3 (C-1′), 128.5 (C-2′), 107.2 (C-3′), 137.2 (C-4′), 107.2 (C-5′), 128.5 (C-6′), 128.6 (C-7′), 121.5 (C-8′)。以上数据与曹雷雷等(2015)报道的数值基本一致,故鉴定化合物8​为hinokiresinol。
​化合物9  ​ 白色粉末,ESI-MS m/z​: 275.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 6.53 (1H, dd, J​ = 11.4, 4.2 Hz), 4.02 (1H, m), 2.57~2.61 (2H, m), 2.51 (1H, m), 2.41 (2H, m), 2.03 (2H, m), 1.62 (2H, m), 1.03 (3H, t, J​ = 7.26 Hz)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 153.6 (C-1), 126.4 (C-2), 87.1 (C-3), 26.3 (C-4), 26.1 (C-5), 36.7 (C-6), 133.1 (C-7), 26.9 (C-8), 23.1 (C-9), 21.7 (C-10)。以上数据与张双等(2024)报道的数值基本一致,故鉴定化合物9​为sedanolide。
​化合物10  ​ 白色粉末,ESI-MS m/z​: 275.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 9.61 (1H, brs, H-7′), 9.03 (1H, dd, J​ = 11.4, 4.2 Hz, H-5′), 8.64 (1H, d, J​ = 11.4 Hz, H-3′), 7.81 (1H, dd, J​ = 11.4, 4.2 Hz, H-4′), 5.42 (1H, dd, J​ = 11.4, 4.2 Hz, H-12), 4.96 (1H, brs, H-6), 4.03 (1H, m, H-3), 2.37 (3H, s, H-21), 1.96 (3H, s, H-18), 1.52 (3H, s, H-19)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 39.6 (C-1), 32.4 (C-2), 70.3 (C-3), 41.7 (C-4), 136.8 (C-5), 120.5 (C-6), 34.7 (C-7), 75.1 (C-8), 46.2 (C-9), 38.1 (C-10), 26.1 (C-11), 74.9 (C-12), 60.3 (C-13), 87.2 (C-14), 35.6 (C-15), 33.7 (C-16), 95.1 (C-17), 12.3 (C-18), 20.7 (C-19), 176.3 (C-20), 157.6 (C-1′), 126.4 (C-2′), 137.6 (C-3′), 123.8 (C-4′), 147.3 (C-5′)。以上数据与Zhao等(2016)报道的数值基本一致,故鉴定化合物10​为rostratamine。
​化合物11​   黄色油状物,ESI-MS m/z​: 171.0 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.73 (1H, d, J​ = 11.4 Hz, H-7), 7.49 (2H, m, H-2, 6), 7.36 (3H, m, H-3, 4, 5), 6.28 (1H, d, J​ = 11.4 Hz, H-8)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 126.9 (C-1), 126.4 (C-2), 127.3 (C-3), 129.6 (C-4), 128.1 (C-5), 127.6 (C-6), 146.4 (C-7), 118.1 (C-8), 173.4 (C-9)。以上数据与Wang等(2009)报道的数值基本一致,故鉴定化合物11​为cinnamicacid。
​化合物12  ​ 淡黄色固体,ESI-MS m/z​: 377.0 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.63 (1H, d, J​ = 11.4 Hz, H-4), 7.21 (1H, s, H-5), 6.84 (1H, s, H-8), 6.25 (1H, d, J​ = 11.4 Hz, H-3), 3.91 (3H, s, 7-OCH3​)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 138.2 (C-1), 156.4 (C-2), 108.5 (C-3), 143.7 (C-4), 108.6 (C-5), 141.5 (C-6), 153.4 (C-7), 97.6 (C-8), 138.3 (C-9), 107.5 (C-10), 96.5 (C-1′), 74.5 (C-2′), 68.2 (C-3′), 70.4 (C-4′), 77.1 (C-5′), 55.8 (7-OCH3​)。以上数据与张美秦等(2024)报道的数值基本一致,故鉴定化合物12​为magnolioside。
​化合物13​   白色针晶,ESI-MS m/z​: 398.0 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.73 (1H, s, 7-OH), 6.42 (1H, s, H-6), 5.37 (1H, dd, J​ = 11.4, 4.2 Hz, H-11), 5.26 (2H, s, H-3), 5.08 (1H, s, H-13), 5.02 (1H, s, H-13), 3.46 (1H, dd, J​ = 11.4, 4.2 Hz, H-10), 2.83 (1H, dd, J​ = 11.4, 4.2 Hz, H-10), 1.91 (3H, s, H-14)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 161.5 (C-1), 132.5 (C-2), 68.7 (C-3), 109.1 (C-4), 141.6 (C-5), 102.4 (C-6), 154.3 (C-7), 103.1 (C-8), 137.1 (C-9), 31.7 (C-10), 87.2 (C-11), 137.5 (C-12), 113.1 (C-13), 18.6 (C-14)。以上数据与Jakupovic等(1987)报道的数值基本一致,故鉴定化合物13​为platypterophathalide。
​化合物14​   白色粉末,ESI-MS m/z​: 212.4 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.93 (1H, d, J​ = 11.4 Hz, H-5), 7.86 (1H, d, J​ = 11.4 Hz, H-8), 7.64 (1H, t, J​ = 11.4 Hz, H-7), 7.41 (1H, t, J​ = 11.4 Hz, H-6), 6.82 (1H, s, H-3)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 132.5 (C-1), 147.3 (C-2), 117.2 (C-3), 175.2 (C-4), 124.2 (C-5), 120.5 (C-6), 131.6 (C-7), 123.5 (C-8), 126.2 (C-9), 134.2 (C-10)。以上数据与胡乐诗等(2023)报道的数值基本一致,故鉴定化合物14​为transtorine。
​化合物15​   白色油状物,ESI-MS m/z​: 359.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 2.28 (2H, t, J​ = 11.4 Hz, H-14), 2.06 (3H, d, J​ = 11.4 Hz, 17-CH3), 1.84 (1H, m, H-5a), 1.61 (3H, d, J​ = 11.4 Hz, 16-CH3), 1.53 (1H, m, H-5β), 1.49 (2H, m, H-13), 1.27~1.31 (12H, m, H-7-12), 1.16 (1H, m, H-6a), 1.09 (1H, m, H-6β)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 151.3 (C-1), 157.9 (C-2), 126.8 (C-3), 113.5 (C-4), 37.8 (C-5), 23.4 (C-6), 29.4 (C-7-12), 25.8 (C-13), 35.1 (C-14), 153.5 (C-15)。以上数据与李绍花等(2024)报道的数值基本一致,故鉴定化合物15​为capillasterolide。
​化合物16  ​ 白色粉末,ESI-MS m/z​: 515.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.71 (2H, m, H-2″, 6″), 7.53 (3H, m, H-3″, 4″, 5″), 6.74 (1H, d, J​ = 16.0 Hz, H-8″), 6.42 (1H, d, J​ = 5.2 Hz, H-3), 5.18 (1H, m, H-1), 4.91 (1H, d, J​ = 11.4 Hz, H-1′), 3.92 (1H, m, H-6), 3.28 (1H, m, H-7)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 103.5 (C-1), 125.9 (C-2), 136.8 (C-3), 98.6 (C-4), 37.1 (C-5), 76.8 (C-6), 60.3 (C-7), 63.1 (C-8), 42.7 (C-9), 67.3 (C-10), 100.3 (C-1′), 75.1 (C-2′), 78.1 (C-3′), 72.6 (C-4′), 79.1 (C-5′), 60.7 (C-6′), 126.8 (C-1″), 130.5 (C-2″), 127.3 (C-3″), 128.3 (C-4″), 127.3 (C-5″), 130.5 (C-6″), 109.2 (C-7″), 145.4 (C-8″)。以上数据与李绍花等(2024)报道的数值基本一致,故鉴定化合物16​为globularin。
​化合物17​   黄色粉末,ESI-MS m/z​: 291.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 8.29 (1H, s, H-2), 8.03 (1H, d, J​ = 11.4 Hz, H-5), 7.49 (2H, d, J​ = 11.4 Hz, H-2′, 6′), 7.08 (2H, d, J​ = 11.4 Hz, H-3′, 5′), 7.02 (1H, dd, J​ = 11.4, 4.2 Hz, H-6), 6.73 (1H, d, J​ = 11.4 Hz, H-8)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 127.6 (C-1), 148.1 (C-2), 124.9 (C-3), 174.2 (C-4), 128.1 (C-5), 114.3 (C-6), 162.5 (C-7), 103.1 (C-8), 155.1 (C-9), 116.2 (C-10), 123.4 (C-1′), 128.6 (C-2′), 113.9 (C-3′), 142.8 (C-4′), 113.9 (C-5′), 128.6 (C-6′)。以上数据与刘翠珍等(2024)报道的数值基本一致,故鉴定化合物17​为芒柄花素。
​化合物18​   白色粉末,ESI-MS m/z​: 215.2 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.61 (1H, d, J​ = 11.4 Hz, H-7), 7.39 (2H, d, J​ = 11.4 Hz, H-2, 6), 6.82 (2H, q, J​ = 11.4 Hz, H-3, 5), 6.31 (1H, d, J​ = 11.4 Hz, H-8), 4.19 (1H, q, J​ = 11.4 Hz, H-1′), 1.28 (3H, t, J​ = 11.4 Hz, H-2′)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 131.7 (C-1), 127.5 (C-2), 117.7 (C-3), 153.2 (C-4), 117.7 (C-5), 127.5 (C-6), 135.2 (C-7), 114.6 (C-8), 158.2 (C-9), 62.6 (C-1′), 18.1 (C-2′)。以上数据与Pontes等(2022)报道的数值基本一致,故鉴定化合物18​为对羟基肉桂酸乙酯。
​化合物19​   黄色粉末,ESI-MS m/z​: 367.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.51 (1H, dd, J​ = 11.4, 4.2 Hz, H-6′), 7.36 (1H, s, H-2′), 6.87 (1H, d, J​ = 11.4 Hz, H-5′), 6.62 (1H, s, H-8), 6.47 (1H, s, H-3), 4.02 (3H, s, H-3′), 3.91 (3H, s, H-6)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 116.5 (C-1), 157.3 (C-2), 104.2 (C-3), 176.2 (C-4), 153.1 (C-5), 133.1 (C-6), 159.1 (C-7), 96.4 (C-8), 153.5 (C-9), 104.6 (C-10), 124.1 (C-1′), 111.2 (C-2′), 150.1 (C-3′), 150.6 (C-4′), 115.6 (C-5′), 22.4 (C-6′), 61.3 (6-OCH3​), 57.1 (3′-OCH3​)。以上数据与贺非凡等(2024)报道的数值基本一致,故鉴定化合物19​为cirsilineol。
​化合物20​   白色晶体,ESI-MS m/z​: 219.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 5.81 (1H, s, H-3), 4.45 (1H, m, H-6), 2.37 (1H, td, J​ = 11.4 Hz, H-7a), 2.04 (1H, ddd, J​ = 11.4, 4.2, 1.8 Hz, H-5a), 1.81 (3H, s, H-10), 1.68 (1H, d, J​ = 11.4 Hz, H-7β), 1.43 (1H, d, J​ = 11.4 Hz, H-5β), 1.39 (3H, s, H-8), 1.31 (3H, s, H-9)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 132.5 (C-1), 173.2 (C-2), 112.5 (C-3), 38.1 (C-4), 48.3 (C-5), 66.7 (C-6), 45.1 (C-7), 26.9 (C-8), 30.8 (C-9), 26.9 (C-10)。以上数据与贺非凡等(2024)报道的数值基本一致,故鉴定化合物20​为地芰普内酯。
​化合物21  ​ 白色针晶,ESI-MS m/z​: 219.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.52 (1H, dd, J​ = 11.4, 4.2 Hz, H-6), 7.43 (1H, d, J​ = 11.4 Hz, H-2), 7.02 (1H, dd, J​ = 11.4 Hz, H-5), 2.53 (3H, s, H-8), 3.94 (3H, s, 4-OCH3​)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 128.4 (C-1), 116.0 (C-2), 149.3 (C-3), 154.1 (C-4), 110.8 (C-5), 122.1 (C-6), 176.2 (C-7), 27.1 (C-8), 57.1 (4-OCH3​)。以上数据与陆彩侠等(2024)报道的数值基本一致,故鉴定化合物21​为acetoisovanillone。
​化合物22​   白色粉末,ESI-MS mm/z​: 357.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 5.91 (1H, s, H-7), 4.04~4.06 (1H, m, H-2), 3.95~3.97 (1H, m, H-3), 3.09~3.13 (1H, m, H-15), 2.41~2.45 (1H, m, H-5), 2.17~2.19 (1H, m, H-15), 1.41~1.43 (1H, m, H-1), 1.74~1.77 (1H, m, H-1), 1.03 (3H, s, 19-CH3), 0.94 (3H, s, 18-CH3)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 38.1 (C-1), 68.2 (C-2), 68.1 (C-3), 33.1 (C-4), 52.3 (C-5), 182.3 (C-6), 123.5 (C-7), 162.6 (C-8), 36.1 (C-9), 40.3 (C-10), 21.7 (C-11), 30.2 (C-12), 54.1 (C-13), 80.2 (C-14), 34.1 (C-15), 25.2 (C-16), 163.5 (C-17), 18.6 (C-18), 25.4 (C-19)。以上数据与徐宏盼等(2024)报道的数值基本一致,故鉴定化合物22​为rubrosterone。
​化合物23  ​ 白色粉末,ESI-MS m/z​: 249.0 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.51 (1H, brs, H-2′), 7.18 (1H, d, J​=11.4 Hz, H-3), 7.09 (bs, 1H, H-4′), 6.91 (1H, d, J​=11.4 Hz, H-6′), 6.86 (1H, dd, J​=11.4, 4.2 Hz, H-5), 2.41 (3H, s, H-10′), 1.57 (6H, s, H-8′,9′)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 135.6 (C-1), 121.5 (C-2), 112.6 (C-3), 143.6 (C-4), 114.9 (C-5), 119.1 (C-6), 127.1 (C-1′), 123.1 (C-2′), 136.2 (C-3′), 126.4 (C-4′), 122.9 (C-5′), 136.2 (C-6′), 76.9 (C-7′), 26.9 (C-8′), 26.9 (C-9′), 20.9 (C-10′)。以上数据与王潇等(2024)报道的数值基本一致,故鉴定化合物23​为didehydroconicol。
​化合物24​   白色油状物,ESI-MS m/z​: 245.1 [M+Na]+​。1​H-NMR (600 MHz, DMSO-d6​) δ​: 7.02 (1H, d, J​ = 11.4 Hz, H-4), 6.31 (1H, d, J​ = 11.4 Hz, H-3), 5.71 (1H, t, J​ = 11.4 Hz, H-3′), 2.47 (1H, d, J​ = 11.4 Hz, H-5′), 2.35 (3H, s, H-1), 2.08 (1H, d, J​ = 11.4 Hz, H-5′), 1.91 (3H, d, J​ = 4.2 Hz, H-9), 1.02 (3H, s, H-7), 0.97 (3H, s, H-8)。13​C-NMR (150 MHz, DMSO-d6​) δ​: 25.1 (C-1), 173.2 (C-2), 127.5 (C-3), 136.4 (C-4), 50.6 (C-5), 43.4 (C-6), 29.3 (C-7), 24.1 (C-8), 19.7 (C-9), 79.3 (C-1′), 154.3 (C-2′), 127.1 (C-3′), 181.3 (C-4′)。以上数据与李振兴等(2024)报道的数值基本一致,故鉴定化合物24​为去氢吐叶醇。
2.2 化合物对乳腺癌细胞抑制活性结果
表1结果显示,与空白对照组比较,化合物14891314161923对MDA-MB-231细胞具有不同程度的抑制作用,其他化合物未表现显著的抑制活性(IC50>50 μmol·L-1)。化合物9对该细胞增殖的IC50值为(19.02±5.34)μmol·L-1,与阳性对照组的(18.62±5.16)μmol·L-1相当(P>0.05)。
1 化合物对MDA-MB-231细胞的抑制活性
Table 1 Inhibitory activities of the compound on MDA-MB-231 cells
注:数据=平均值±标准差,n=3。与阳性对照组比较,*表示P<0.05。
Note: Data=x¯±s, n=3. Compared with the positive control group,* indicates P<0.05.
3 讨论与结论
乳腺癌是全球最常见的女性恶性肿瘤之一,严重威胁女性的生命健康。尽管目前乳腺癌的治疗手段多样,包括手术、化疗、放疗、内分泌治疗及靶向治疗等,但是仍面临诸多挑战(Pearce et al., 2025)。西药化疗在杀伤肿瘤细胞的同时,往往对正常细胞也产生较大毒性,导致患者出现严重的不良反应,降低生活质量;部分患者对内分泌治疗或靶向治疗耐药,使得治疗效果不佳。因此,寻找安全有效的新型抗癌药物或辅助治疗药物具有重要的临床意义(Zerang et al., 2025)。中药因其多成分、多靶点的作用特点,在肿瘤治疗方面展现出独特优势,从中药中筛选抗癌活性成分已成为研究热点之一。延龄草作为传统中药,已有研究表明其具有一定的抗癌活性,对其进行深入研究有望为乳腺癌治疗提供新的思路和药物来源。
本研究从延龄草中分离鉴定出24个化合物,均为首次从延龄草中分离鉴定,其中化合物13689131423为首次从延龄草属植物中分离鉴定。评价所得化合物对乳腺癌MDA-MB-231细胞的抑制活性,实验结果显示,延龄草提取物中多种单体化合物对MDA-MB-231细胞的增殖均具有不同程度的抑制活性。计算得到的 IC50值表明,不同单体化合物对MDA-MB-231细胞的抑制能力存在差异,但化合物14891314161923均能有效抑制细胞增殖,其中化合物9对细胞增殖的抑制率较高,IC50值为(19.02±5.34)μmol·L-1,提示化合物9可能具有潜在的抗乳腺癌活性。
本研究丰富了延龄草药理作用的物质基础,为乳腺癌新药的研发提供了一定的帮助。
1 化合物 1-24 的化学结构
Fig. 1 Chemical structures of compounds 1-24
1 化合物对MDA-MB-231细胞的抑制活性
Table 1 Inhibitory activities of the compound on MDA-MB-231 cells
CAO L L, TIAN H Y, WANG Y S, et al. , 2015. Chemical constituents in the fruits of mangrove plant Sonneratia apetala Buch. Ham. [J]. Journal of Tropical Oceanography, 34(1): 77-82.
[曹雷雷, 田海妍, 王友绍, 等, 2015. 红树植物无瓣海桑果实的化学成分研究 [J]. 热带海洋学报, 34(1): 77-82.]
FENG X T, SUN Y P, LI G L, et al. , 2024. Chemical constituents of Syringa oblata leaves [J]. Central South Pharmacy, 22(12): 3206-3214.
[冯小涛, 孙延平, 黎冠兰, 等, 2024. 紫丁香叶化学成分研究 [J]. 中南药学, 22(12): 3206-3214.]
FU X Y, LI L X, LI X Y, et al. , 2024. Chemical constituents from stems and leaves of Acronychia pedunculata and their anti-rheumatoid arthritis activities [J]. Chinese Traditional and Herbal Drugs, 55(23): 7932-7938.
[傅小雅, 李林轩, 李昕怡, 等, 2024. 山油柑枝叶中化学成分及其抗类风湿性关节炎活性研究 [J]. 中草药, 55(23): 7932-7938.]
HE F F, ZHAO N T, YAN X J, et al. , 2024. Chemical constituents from the methanol fraction of Premna fulva leaves and their anti-inflammatory activities [J]. Chinese Traditional Patent Medicine, 46(6): 1894-1899.
[贺非凡, 赵宁涛, 颜小捷, 等, 2024. 战骨叶甲醇部位化学成分及其抗炎活性研究 [J]. 中成药, 46(6): 1894-1899.]
HU L S, TAN S L, ZHU Z Y, et al. , 2023. Study on chemical constituents from stems of Entada phaseoloides [J]. Chinese Traditional and Herbal Drugs, 54(20): 6596-6602.
[胡乐诗, 谭少丽, 朱子云, 等, 2023. 过岗龙的化学成分研究 [J]. 中草药, 54(20): 6596-6602.]
JAKUPOVIC J, SCHUSTER A, SUN H, et al. , 1987. Prenylated phthalides from Anaphalis araneosa and Helichrysum platypterum [J]. Phytochemistry, 26(2): 580-581.
KHAN K M, NAHAR L, AL-GROSHI A, et al. , 2016. Cytotoxicity of the roots of Trillium govanianum against breast (MCF7), liver (HepG2), lung (A549) and urinary bladder (EJ138) carcinoma cells [J]. Phytotherapy Research, 30(10): 1716-1720.
LI S H, CHEN Y F, QIAN H S, et al. , 2024. Chemical constituents of the ethyl acetate fraction of Aralia chinensis Linn. var. nuda Nakai [J]. Journal of Yunnan University of Chinese Medicine, 47(4): 61-65.
[李绍花, 陈宇凡, 钱海珊, 等, 2024. 白背叶楤木乙酸乙酯部位化学成分研究 [J]. 云南中医药大学学报, 47(4): 61-65.]
LI X P, ZHANG Y Y, LI L, et al. , 2017. Research progress on chemical constituents and pharmacological effects of Trillium tschonoskii Maxim [J]. Special Wild Economic Animal and Plant Research, 39(2): 71-78.
[李小沛, 张亚玉, 李乐, 等, 2017. 延龄草的化学成分及药理作用研究进展 [J]. 特产研究, 39(2): 71-78.]
LI Z X, SHAN X M, BI G M, et al. , 2024. Separation and identification of chemical components of lantern grass Ⅱ [J]. Journal of Shenyang Pharmaceutical University, 41(10): 1316-1322.
[李振兴, 单雪梅, 毕光明, 等, 2024. 灯笼草化学成分的分离和鉴定Ⅱ [J]. 沈阳药科大学学报, 41(10): 1316-1322.]
LIU C Z, FENG S Q, LIN X J, et al. , 2024. Identification of chemical constituents of modified Yupingfengsan formula [J]. Chinese Pharmacy, 35(18): 2225-2231.
[刘翠珍, 冯思琪, 林秀娟, 等, 2024. 玉屏风散加味方化学成分鉴定 [J]. 中国药房, 35(18): 2225-2231.]
LU C X, KONG C H, TANG X, et al. , 2024. Chemical constituents from n-butyl alcohol extracts of Moutan Cortex [J]. Research and Development of Natural Products, 36(10): 1714-1720.
[陆彩侠, 孔垂皓, 唐旭, 等, 2024. 牡丹皮正丁醇部位化学成分研究 [J]. 天然产物研究与开发, 36(10): 1714-1720.]
NIU X M, LI S H, LI M L, et al. , 2002. Cytotoxic ent-kaurane diterpenoids from Isodon oeriocalyx var. laxiflora [J]. Planta Medica, 68(6): 528-533.
PEARCE A, CARTER S, FRAZER M H, et al. , 2025. Implementing artificial intelligence in breast cancer screening: Women’s preferences [J]. Cancer, 131(9): e35859.
PONTES M C, CAVALCANTE N B, LEAL A E B P, et al. , 2022. Chemical constituents and antibacterial activity of Bromelia laciniosa (Bromeliaceae): Identification and structural characterization [J]. Phytomedicine Plus, 2(1): 175-179.
SULAIMAN N S, OTHMAN A M, DIN M F M, et al. , 2024. Chemical constituents from Cyathostemma wrayi King and their chemophenetic significance [J]. Biochemical Systematics and Ecology, 117(11): 916-919.
SEIDEL V, BAILLEUL F, WATERMAN P G, 1999. Goniothalamusin, a linear acetogenin from Goniothalamus gardneri [J]. Phytochemistry, 52(7): 1101-1103.
WANG X, CUI W L, WANG S Q, 2024. Chemical constituents of Marsupella commutata (Limpr.) Bernet. [J]. Central South Pharmacy, 22(8): 1971-1975.
[王潇, 崔伟亮, 王姝麒, 2024. 锐裂钱袋苔化学成分研究 [J]. 中南药学, 22(8): 1971-1975.]
WANG X W, ZHANG H P, CHEN F, et al. , 2009. A new lignan from Gynostemma pentaphyllum [J]. Chinese Chemical Letters, 20(5): 589-591.
Wuhan Institute of Botany, Chinese Academy of Sciences, 2003. Flora of Hubei Province: Vol. 4 [M]. Wuhan: Hubei Science and Technology Press: 453-454.
[中国科学院武汉植物所, 2003. 湖北植物志: 第四卷 [M]. 武汉: 湖北科技出版社: 453-454.]
XU H N, WANG H X, CHEN L, et al. , 2024. Chemical constituents from petroleum ether extract of Salacia obovatilimba [J]. Chinese Traditional and Herbal Drugs, 55(20): 6838-6844.
[许浩楠, 王浩鑫, 陈林, 等, 2024. 河口五层龙石油醚部分的化学成分研究 [J]. 中草药, 55(20): 6838-6844.]
XU H P, NIE W, LU L H, et al. , 2024. Study on chemical constituents of Paris polyphylla Smith var. yunnanensis(Ⅱ) [J]. Guangzhou Chemical Industry, 52(18): 62-64.
[徐宏盼, 聂伟, 陆礼和, 等, 2024. 滇重楼化学成分研究(Ⅱ) [J]. 广州化工, 52(18): 62-64.]
XU J J, HUANG X F, TAN Q G, 2024. Chemical constituents from Illigera celebica and their cytotoxicity activity [J]. Chinese Journal of Pharmacy, 59(24): 2315-2321.
[徐娟娟, 黄小芳, 谭钦刚, 2024. 宽药青藤化学成分及其细胞毒活性研究 [J]. 中国药学杂志, 59(24): 2315-2321.]
ZERANG N, MIRJAFARY Z, SAEIDIAN H, et al. , 2025. Enhancing palbociclib efficacy with low toxicity in breast cancer using polycaprolactone-based nanocarriers [J]. Results in Chemistry, 15: 102283.
ZENG X C, ZHANG Y Q, HUANG S C, et al. , 2019. Growth inhibiting and promoting apoptosis of Trillium saponins on xenografts of breast cancer cells MDA-MB-231 in nude mice [J]. Modern Oncology, 27(6): 952-955.
[曾小聪, 张远起, 黄胜超, 等, 2019. 延龄草总皂苷抑制乳腺癌细胞MDA-MB-231裸鼠移植瘤的增殖和促进凋亡作用 [J]. 现代肿瘤医学, 27(6): 952-955.]
ZHANG M Q, NIE Y S, WANG Y, et al. , 2024. Study on phenylpropyl chemical components in water winter melon [J]. Chinese Medicinal Materials, 47(4): 887-891.
[张美秦, 聂雨杉, 汪洋, 等, 2024. 水冬瓜中苯丙素类化学成分研究 [J]. 中药材, 47(4): 887-891.]
ZHANG S, KUANG W J, YU Z G, et al. , 2024. Study on the chemical components and antioxidant activity of Yangxue Qingnao alcohol extract [J]. Tianjin Pharmacy, 36(5): 10-17.
[张双, 旷文静, 于治国, 等, 2024. 养血清脑醇提浸膏化学成分及抗氧化活性研究 [J]. 天津药学, 36(5): 10-17.]
ZHAO J W, CHEN F Y, GAO L J, et al. , 2016. Two new 8, 14-seco-pregnane steroidal aglycones from roots of Cynanchum bungei [J]. Natural Product Communications, 11(12): 1797-1800.
ZHONG L Z, YUE M Z, YAN Y W, et al. , 2013. Study on chemical constituents in the roots and rhizome of Trillium tschonoskii (Ⅲ) [J]. Journal of Chinese Medicinal Materials, 36(11): 1779-1782.